CClinicalTrials.gg
CompletedNCT03375996MYFLACSUpdated Aug 22, 2024

Evaluation of a Protocol of Pupil Dilation Before Laser-assisted Cataract Surgery

An observational study in Cataract Surgery, sponsored by CHU de Reims. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by CHU de Reims · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

Laser-assisted cataract surgery is an innovative and growing procedure to improve the safety and results of modern cataract surgery. However, this technique faces to some obstacles: economics in the one hand due to the cost and time spent for the laser procedure before the conventional surgery, and technical in the other hand, especially due to some loss of pupil dilation during the surgery, which is highly important to ensure a perfect procedure. The present study aims at assessing a pharmacological protocol to maintain an accurate pupil dilation all along the surgery in order to improve the whole procedure.

Read the detailed description

Femtosecond laser-assisted cataract surgery (FLACS) is a major surgical development that would allow systematization of surgery and even improved safety of the procedure. The development of this new surgical technique must now face certain obstacles, in particular (i) financial considering the extra cost generated by the use of the laser and (ii) technique due to the need to re-learn certain gestures and certain variations related to the laser procedure and more specifically the instability of the pupillary mydriasis (dilatation) during the actual surgery. The use of a systematic preoperative pharmacological mydriasis protocol should allow maximum intraoperative mydriasis to be maintained, allowing satisfactory surgery throughout the procedure. Several drugs or medical devices are now indicated in cataract surgery, but their effectiveness has not been specifically evaluated for the laser technique. This study could thus make it possible to validate or not a protocol of mydriasis that could make consensus in the future for the practice of FLACS.

02

Conditions studied

  • Cataract Surgery

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with cataract scheduled for laser-assisted cataract surgery

Inclusion criteria

  • Patient with unilateral or bilateral cataract requiring a cataract surgery
  • Patient scheduled for laser-assisted cataract surgery

Exclusion criteria

exclusion criteria :

  • Limitation due to laser procedure (little orbits, corneal scares, lack of pharmacological mydriasis at the inclusion visit)
  • Subject with general medication influencing iris state and/or pupil dilation (alpha-agonist, psychotropic drugs)
  • Subject unable to give informed consent
  • minors
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
60 participants (actual)
Patient registry
No

Groups and cohorts

  • FLACS group

    Patient presenting cataract and scheduled for laser-assisted cataract surgery

    Drug: cyclopentolate 0.5% eye drops

Interventions

  • Drugcyclopentolate 0.5% eye drops

    cyclopentolate 0.5% eye drops and measurement of the pupillary mydriasis (dilatation)

05

What researchers measure

Primary outcomes

  1. Pupil diameter > 6 mm all along the surgical procedure

    a posteriori pupil measurement using the peroperative movie recorded via the operative microscope during each surgery.

    Time frame: Day 0

Secondary outcomes

  1. Pupil diameter variation at each time of the surgery

    Time frame: Day 0

  2. Surgeon satisfaction

    questionnaire

    Time frame: Day 0

06

Study locations

1 site
  • Chu Reims
    Reims, 51092, France
07

Registry details

Key details

Study ID
NCT03375996
Lead sponsor
CHU de Reims
Responsible party
Sponsor
First posted
Dec 18, 2017
Start date
Jun 1, 2018
Primary completion
Aug 21, 2024
Completion
Aug 21, 2024
Last update
Aug 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion